Repligen Corporation to Present at Upcoming Investor Conferences
Repligen Corporation (NASDAQ:RGEN) has announced its participation in two virtual investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Repligen Corporation (NASDAQ:RGEN) has announced its participation in two virtual investor conferences. CEO Tony J. Hunt will join the William Blair 41st Annual Growth Stock Conference on June 1 at 1:40 p.m. EST and the Jefferies Virtual Healthcare Conference on June 3 at 2:30 p.m. EST. These discussions will be available via live webcast and can be replayed afterward. Repligen focuses on developing innovative bioprocessing technologies for biopharmaceutical manufacturers globally.
Details
News Market Reaction – RGEN
The recorded move for RGEN in the trading session of this news was +1.57%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virtually at two upcoming investor conferences.
- William Blair 41st Annual Growth Stock conference being held June 1 - 3. Tony J. Hunt, President and Chief Executive Officer, will participate in a fireside chat on Tuesday, June 1, at 1:40 p.m. EST.
- Jefferies Virtual Healthcare Conference being held June 1 - 3. Tony J. Hunt, President and Chief Executive Officer and Jon K. Snodgres, Chief Financial Officer, will participate in a fireside chat on Thursday, June 3, at 2:30 p.m. EST.
A live webcast of the discussions will be accessible through the Investor Relations section of the Company’s website, and will be available for replay for a limited period of time following the conference event.
About Repligen Corporation
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that increase efficiencies in the process of manufacturing biological drugs. Our primary customers are biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our corporate headquarters are located in Waltham, Massachusetts, with additional administrative and manufacturing operations worldwide. The majority of our manufacturing sites are located within the U.S. (California, Massachusetts, New Jersey and New York), and outside of the U.S. we have sites in Estonia, Germany, Ireland, the Netherlands and Sweden.
Repligen Contact:
Sondra S. Newman
Global Head of Investor Relations
(781) 419-1881
investors@repligen.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.